drugset / Trial / NCT03736850
Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open label, sequential-cohort, dose escalation \& expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose (MTD）, if any, Recommended Phase II Doses (RP2Ds) and regimen of CS3006. The study is composed of two parts: Part 1 for dose escalation and Part 2 for dose expansion.
Timeline
- Start
- 2018-10-19
- Primary completion
- 2020-05-15
- Completion
- 2020-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS3006 | Unknown | — | — |
Indications
No indication recorded.